Bourdage Sets Out Sandoz’ Biosimilar Growth Ambitions
Adding At Least One Molecule Per Year But Maintaining ‘Selective’ Approach
Sandoz plans to add at least one new molecule per year to its biosimilar development plans, while still maintaining a “selective” approach to targets, head of biopharmaceuticals Pierre Bourdage explains in the second part of an exclusive interview with Generics Bulletin.
